Latest News

(UroToday.com) The 2021 American Society for Radiation Oncology (ASTRO) Hybrid Annual Meeting included a joint ASTRO/SNMMI session on prostate cancer molecular imaging and radiotheranostics and a presentation by Dr. Ana Kiess discussing the current and future management paradigms for metastatic castration-resistant prostate cancer (mCRPC). Dr. Kiess notes that Radium-223 is a calcium mimic that directly targets […]

(UroToday.com) The 2021 American Society for Radiation Oncology (ASTRO) Hybrid Annual Meeting included a Prostate Cancer Oligometastases session and a presentation by Dr. Ryan Phillips discussing where to focus the beam for treating newly diagnosed oligometastatic prostate cancer.

Patients with T1 urinary bladder cancer (UBC) are at high risk for recurrence and progression. [1] However, the prognosis depends on several concomitant factors. First and foremost, an accurate diagnosis is imperative to appropriate disease management. Under or over-staging Due to conventional transurethral resection techniques resulting in fragmentation and cauterisation of the tissue, the pathological […]

Cardinal Health will explore how to better standardize real world evidence for use in regulatory decisions San Francisco, CA (UroToday.com) — Cardinal Health (NYSE: CAH) announced today it has been awarded a $750,000 contract by the U.S. Food and Drug Administration (FDA) to implement an 18-month real world evidence (RWE) study as part of the […]

Optimizing pain management strategies in penile implantation has historically been a challenge to urologists assuming care of patients post-operatively. In addition to the complex pathophysiology of male genital pain, the responsibility of opioid stewardship in the face of the ongoing narcotics epidemic presents its own set of challenges to experienced implanters.

Radical nephroureterectomy is the mainstay of surgical treatment for upper tract urothelial carcinoma (UTUC), a disease which comprises approximately 5% of urothelial malignancies. Minimally-invasive and nephron-sparing interventions have been explored, although thus far have not shown comparable oncologic outcomes except in a relatively narrow set of patients.

Significantly increased risks of cardiovascular disease occur in testicular cancer survivors given cisplatin-based chemotherapy. The postulated mechanism of platinum-based chemotherapy’s vascular toxicity has been thought secondary to its different early- and late- effects on vascular injury, endothelial dysfunction, and induction of a hypercoagulable state.

Through elucidating the genetic mechanisms of drug sensitivity, precision medicine aims to improve patient selection and response to therapy. Exceptional responders are patients that exhibit exquisite and durable responses to targeted therapy, providing a rare opportunity to identify the molecular basis of drug sensitivity.

To analyze if exposure to sunitinib in the SURTIME trial which investigated opposite sequences of cytoreductive nephrectomy (CN) and systemic therapy is associated with the overall survival (OS) benefit observed in the deferred CN arm.

While hypofractionated (HF) radiation therapy (RT) is recognized as a suitable treatment for low and intermediate risk prostate cancer, it is not yet the standard of care. As HF RT requires the patient to attend fewer appointments, it is potentially easier for patients to complete than conventional fractionation (CF) RT.